Staszewski S - Search Results

1

Staszewski S. Staszewski S. Int J Clin Pract Suppl. 1999 Jun;103:35-8. Int J Clin Pract Suppl. 1999. PMID: 10622042 Review.

2

Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC.

Staszewski S. Staszewski S. Int J Clin Pract Suppl. 1999 Jun;103:10-5. Int J Clin Pract Suppl. 1999. PMID: 10622037 Clinical Trial.

3

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M. Miller V, et al. Among authors: staszewski s. AIDS. 2000 Jan 28;14(2):163-71. doi: 10.1097/00002030-200001280-00012. AIDS. 2000. PMID: 10708287 Clinical Trial.

4

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team. Staszewski S, et al. JAMA. 2001 Mar 7;285(9):1155-63. doi: 10.1001/jama.285.9.1155. JAMA. 2001. PMID: 11231744 Clinical Trial.

5

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.

Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G. Staszewski S, et al. AIDS. 1998 Nov 12;12(16):F197-202. doi: 10.1097/00002030-199816000-00001. AIDS. 1998. PMID: 9833847 Clinical Trial.

6

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA. Miller V, et al. Among authors: staszewski s. AIDS. 1998 May 7;12(7):705-12. doi: 10.1097/00002030-199807000-00006. AIDS. 1998. PMID: 9619801

7

HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors.

Staszewski S, DeMasi R, Hill AM, Dawson D. Staszewski S, et al. AIDS. 1998 Oct 22;12(15):1991-7. doi: 10.1097/00002030-199815000-00010. AIDS. 1998. PMID: 9814867

8

Virological response to protease inhibitor therapy in an HIV clinic cohort.

Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, Helm EB, Hill A, Phillips A. Staszewski S, et al. AIDS. 1999 Feb 25;13(3):367-73. doi: 10.1097/00002030-199902250-00009. AIDS. 1999. PMID: 10199227

9

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Staszewski S, et al. N Engl J Med. 1999 Dec 16;341(25):1865-73. doi: 10.1056/NEJM199912163412501. N Engl J Med. 1999. PMID: 10601505 Free article. Clinical Trial.

10

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. Miller V, et al. Among authors: staszewski s. AIDS. 2000 Dec 22;14(18):2857-67. doi: 10.1097/00002030-200012220-00007. AIDS. 2000. PMID: 11153667

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters